The aim of this study is to analyze benefits and disadvantages of the IdyllaTM system for the detection of EGFR mutations in a series of 18 NSCLC patients whose mutated status was already known by pyrosequencing, which is our reference method in the laboratory, and accredited according to the ISO 15189 standard (http://www.cofrac.fr/en/organismes/fiche.php?entite_id=82017619). This evidence concerns the gene EGFR and non-small cell lung carcinoma.